Sign in to Peak Brain Path
Sign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksSign in to access your courses, books, and progress tracker. New here? Signing in creates your account automatically.
Want to explore courses first?
Browse courses and booksModule 15
Chapter 15 · 1.5 h · 10 quiz items · pass at 80%
This module carries the chemical-signaling portion of BCIA Domain II (and bridges to the medication content of Domain V) and the IQCB synapses-and-neurotransmitters topic. The quiz proves the learner can separate ionotropic from metabotropic transmission, place the glutamate/GABA balance behind rhythm, and say why medication has to be known before a map is read.
The signal a brain trainer reads is electrical, but the electricity is governed by chemistry. Every post-synaptic potential of Chapter 2 began with a neurotransmitter crossing a synapse, and the balance of those transmitters sets how excitable the cortex is and therefore what rhythm it produces. This is also the reason medications and substances show up on the map at all, which is the handoff point to Your Brain on Drugs. This chapter covers the physiology of the chemistry. That book covers the pharmacology. Knowing the physiology is what lets a practitioner understand why a medicated brain is not the same brain on the map.
When an action potential reaches the end of an axon, it triggers the release of neurotransmitter molecules, which cross the narrow synaptic gap and bind receptors on the receiving cell (Kandel et al., 2021). Some receptors are ionotropic: binding opens an ion channel directly and produces a fast post-synaptic potential, the quick excitatory or inhibitory nudges of Chapter 2. Others are metabotropic: binding sets off slower internal signaling that modulates the cell's responsiveness over a longer timescale, changing not just whether it fires now but how it responds to everything for seconds or minutes. After acting, the transmitter is cleared, by reuptake back into the releasing cell or by enzymatic breakdown, which ends the signal and resets the synapse. These molecular events are the origin of the graded post-synaptic potentials that summate into the EEG.
It helps to know the main receptor families a candidate is expected to recognize, because the fast-versus-slow distinction maps onto specific channels. On the fast, ionotropic side: glutamate acts on AMPA receptors for ordinary fast excitation and on NMDA receptors, the coincidence detectors of Chapter 13, for plasticity. GABA acts on GABA-A receptors for fast inhibition, opening a chloride channel, and acetylcholine acts on nicotinic receptors for fast excitation. On the slow, metabotropic side, working through internal second-messenger cascades rather than opening a channel directly: GABA-B receptors for prolonged inhibition, the metabotropic glutamate receptors, and the receptors for the modulatory transmitters (most dopamine, norepinephrine, serotonin, and muscarinic acetylcholine receptors). The pattern to carry is simple: ionotropic receptors do the fast, point-to-point signaling that builds the post-synaptic potentials of the EEG, while metabotropic receptors set the slower background tone, the gain that the modulatory systems adjust.
[[FIG: FIG-23 – Excitation, inhibition, and rhythm – QUARTER PAGE – a glutamatergic excitatory input and a GABAergic inhibitory interneuron gating a principal cell, with timed inhibition carving activity into a rhythm HERE]]
Two transmitters do most of the fast work, and their balance is fundamental. Glutamate is the brain's main excitatory transmitter, pushing receiving cells toward firing. GABA is the main inhibitory transmitter, pushing them away from firing (Purves et al., 2018). The balance between glutamatergic excitation and GABAergic inhibition sets the overall excitability of the cortex, and excitability shapes rhythm. Inhibition in particular is central to pacing oscillations, because well-timed inhibition is what carves a continuously active population into a synchronized rhythm: when a population of cells is silenced together and then released together, it fires in step, and stepping in step is what produces a readable rhythm by the logic of Chapter 3. Much of what looks like rhythm generation is, underneath, the rhythmic gating of excitation by inhibition. The mechanisms by which inhibitory networks pace fast oscillations such as gamma are well characterized (Buzsáki & Wang, 2012).
[[FIG: FIG-22 – Neurotransmitter projection systems – HALF PAGE – midsagittal brain showing dopamine, norepinephrine (locus coeruleus), serotonin (raphe), and acetylcholine (basal forebrain) origins with their broad projections HERE]]
Layered on top of fast excitation and inhibition are the modulatory systems, small nuclei with wide-reaching projections that set the tone of the whole cortex rather than carrying specific messages. Dopamine supports reward learning, motivation, and aspects of attention. Reduced dopaminergic function is implicated in attention disorders (Gold et al., 2014). Norepinephrine, projected broadly from the locus coeruleus in the brainstem, tracks arousal and salience and sharpens the cortex's response to important events, a key player in the ascending arousal system of Chapter 7. Acetylcholine supports attention and cortical activation and is central to the wake-promoting machinery, also covered in that chapter. Serotonin modulates mood, sleep, and many slower regulatory processes. These systems do not carry detailed sensory content. They set the gain, and changing their tone changes the EEG across the board.
The anatomy underneath is worth holding, because it explains how so small a change can move so much of the map. Each modulatory transmitter is made by a compact cluster of cells and broadcast from there across wide territory. Dopamine comes from the midbrain, the substantia nigra and the ventral tegmental area, reaching the striatum of Chapter 11 and the frontal cortex. Norepinephrine comes from a single small pontine nucleus, the locus coeruleus, whose axons fan out to nearly the entire cortex. Serotonin comes from the raphe nuclei along the brainstem midline, and acetylcholine from the basal forebrain and brainstem. A few thousand cells in each case set the tone of billions. That architecture is why a drug or a lesion at one of these tiny sources is felt everywhere on the scalp, and why arousal and attention, which these broadcasts govern, move the whole recording rather than any one site.
One modulator works on a slower clock than the rest and earns its own mention, because it is the chemistry behind the drowsiness that contaminates so many recordings. Adenosine accumulates in the brain across the waking day as a byproduct of the energy metabolism that keeps neurons running, and as it builds it damps the wake-promoting systems and tilts the cortex toward sleep. This rising tide is the homeostatic sleep pressure that makes a long day end in heaviness: the longer the waking, the more adenosine, the stronger the pull toward sleep, which sleep then clears overnight. Its relevance to the map is direct. A client recorded late in a long day carries high sleep pressure, and the slowed, drowsy record that follows is adenosine doing its work, not a stable trait. It is also why caffeine moves the EEG at all: caffeine blocks adenosine's receptors, lifting the brake and restoring alertness, which is the same reason a coffee an hour before a session suppresses slow activity and shifts the picture. The arousal systems of Chapter 7 set the moment-to-moment dial. Adenosine sets the slow background pressure that climbs across the day and is discharged by sleep.
The chemistry described so far is not identical from one brain to the next. Common genetic variants tune these systems, and some of that tuning shows up on the EEG as a stable trait rather than as pathology. A brain trainer who knows this is less likely to treat a heritable pattern as damage.
Three examples make the point. The COMT enzyme degrades dopamine and norepinephrine in the prefrontal cortex, and a common variant slows that breakdown. Individuals with the slow-breakdown form tend to hold more prefrontal dopamine at rest, and the variant has been associated with a slower individual alpha peak frequency, a posterior rhythm peaking nearer 8 to 9 hertz than 10 to 11 (Chapter 6). That is genetic variation in the speed of the brain's clock, not a lesion, and it can be mistaken for the frontal-theta picture of attention disorders despite arising from a different mechanism. The link between COMT and dopaminergic tone is well established, but whether it extends to a direct effect on alpha frequency remains an open question, so the claim belongs in the "plausible, not settled" column.
The GABA system varies too. Variants in the genes for GABA-A receptor subunits affect inhibitory function and have been associated with a low-voltage, fast, beta-dominant EEG, the kind of desynchronized, hyperexcitable pattern that often travels with anxiety and a strong familial component. People with this pattern frequently find GABAergic substances such as alcohol and benzodiazepines intensely calming, not from weakness but because their receptors are configured to respond robustly to GABAergic modulation. Reframing that as neurobiology rather than character is part of reading the map honestly. What follows from such a pattern, whether in training or in substance regulation, is a clinical-decision question for the coaching and pharmacology literature. The physiological point here is only that the receptor configuration is constitutional, not a flaw of will. The specific gene-to-pattern links await firmer replication and should be held loosely.
Dopamine-system genes (the receptor and transporter variants associated with novelty-seeking and attention traits) likely shape frontal asymmetry, theta-beta balance, and baseline approach motivation, without determining any diagnosis.
The honest frame is the one to carry. Gene-to-EEG correlations are real but modest, typically explaining a small fraction of the variance, and most practitioners infer a heritable contribution from the map plus the history rather than from genetic testing. The tells that a deviation is constitutional rather than acquired are consistent: it is stable across recordings regardless of state or medication, it converges with family history, and it aligns with a lifelong pattern of substance response. The treatment implications of these genetically-influenced patterns belong to Your Brain on Drugs. The reason a gene can shape a rhythm at all is the chemistry of this chapter.
The glutamate-GABA balance is not just a dial on excitability. It is what keeps the cortex in a workable operating range, poised between too little activity and too much. Push the balance too far toward excitation, by reducing inhibition or boosting excitation, and the cortex tips toward hypersynchrony and, at the extreme, seizure: a runaway recruitment in which huge populations fire together, which is why a seizure produces such large, rhythmic EEG. Push it too far toward inhibition, with a sedating drug for instance, and the cortex slows and quiets. The healthy resting EEG lives in the narrow band between these extremes, and much of what medications do to the map is shift the balance one way or the other.
This is also why inhibition deserves more respect than its quiet name suggests. As the balance above showed, well-timed inhibition is what imposes the synchrony Chapter 3 ties to amplitude, so when a brain trainer reads a rhythm they are reading, in part, the work of inhibition organizing excitation in time. The chemistry does not just turn the cortex up and down. It carves the cortex's activity into the rhythms the electrode reads.
Put the layers together and the chapter closes the book's loop. Fast glutamate and GABA signaling set moment-to-moment excitability and, through timed inhibition, pace the oscillations. The modulatory systems set the background tone that determines arousal and attention. Shift any of these, through fatigue, through an imbalance, or through a drug, and the rhythm shifts with it. This is precisely why a resting QEEG recorded on a medication shows the medication and not only the person, and why two clients with the same complaint can produce different maps if one is medicated and one is not. The systematic account of which substances move which features, and in which direction, lives in Your Brain on Drugs. The reason any of it is possible lives here, in the chemistry that underwrites the electrical signal.
A client on a benzodiazepine for anxiety records a map that shows abundant fast beta activity, especially frontally. Read without the chemistry, this looks like a hyperaroused, anxious brain, the very picture the client describes, and the temptation is to treat the beta as the anxiety. The chemistry reframes it. Benzodiazepines act on GABA, the main inhibitory transmitter, and a well-known consequence is an increase in fast beta activity on the EEG, a drug signature layered on top of whatever the person's brain does unmedicated. The beta here is substantially the medication talking, not a clean read of the client's arousal. The disciplined move is to know what is on board, to read the map as a medicated map, and to coordinate with the prescriber rather than to chase a beta that the drug is producing. The systematic catalog of which drugs produce which signatures is Your Brain on Drugs. The reason a drug can do this at all is the chemistry in this chapter.
A practitioner compares a client's two maps, recorded months apart, and reads the difference as treatment progress. The chemistry counsels one question first: did the medication change between recordings? A new stimulant, an adjusted benzodiazepine, a discontinued antidepressant, each moves the EEG through the systems in this chapter, and the shift can swamp or mimic any change from training. Before attributing a map difference to the work, account for the chemistry that was on board each day.
What this means for the signal: the electrical rhythm sits on a chemical substrate. Excitation-inhibition balance and the modulatory systems explain why arousal, attention, and drugs all move the map, and they connect the chemistry of a single synapse back to the line on the screen. Understanding this is what turns a medicated recording from a confusing exception into an expected, readable consequence of the chemistry at work.
Key points
Mnemonic (the four modulators): Don't Notice A Sound (Dopamine, Norepinephrine, Acetylcholine, Serotonin).
Check yourself
trimmings/09-eeg-genetics.md (COMT/alpha, GABA-A/LVF, dopamine genes), re-voiced
with the source's honest hedging preserved. Gate candidates if hard cites wanted:
COMT-cognition (Egan 2001), GABRA2-alcohol (Edenberg 2004); Arns (2012, verified)
for phenotype-medication response. Treatment implications: Your Brain on Drugs.Ch 2 (synaptic signaling), Ch 7 (arousal neuromodulators), Ch 13 (modulators gate plasticity), Your Brain on Drugs (medication/substance effects on EEG).